Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis
-
Published:2021-03
Issue:
Volume:159
Page:103241
-
ISSN:1040-8428
-
Container-title:Critical Reviews in Oncology/Hematology
-
language:en
-
Short-container-title:Critical Reviews in Oncology/Hematology
Author:
Bersanelli MelissaORCID,
Buti SebastianoORCID,
Giannatempo Patrizia,
Raggi Daniele,
Necchi Andrea,
Leonetti Alessandro,
Banna Giuseppe Luigi,
Petrelli FaustoORCID
Subject
Oncology,Hematology
Reference47 articles.
1. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study;Apolo;J. Clin. Oncol.,2017
2. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study;Balar;Lancet Oncol.,2017
3. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial;Balar;Lancet,2017
4. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N. Engl. J. Med.,2017
5. Tumour mutational burden as a driver for treatment choice in resistant tumours (and beyond);Bersanelli;Lancet Oncol.,2020
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献